.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,497,277

« Back to Dashboard

Claims for Patent: 8,497,277

Title:Inhibitors of Bruton's tyrosine kinase
Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
Inventor(s): Honigberg; Lee (San Francisco, CA), Verner; Erik (Belmont, CA), Pan; Zhengying (Austin, TX)
Assignee: Pharmacyclics, Inc. (Sunnyvale, CA)
Application Number:13/312,606
Patent Claims: 1. A method for treating a B-cell proliferative disorder comprising administering to a subject in need thereof a therapeutically effective amount of an irreversible covalent Btk inhibitor having the structure of Formula (A) ##STR00057## wherein A is N; R.sub.1 is L.sub.2-(substituted aryl), where L.sub.2 is a bond; R.sub.2 and R.sub.3 are independently selected from H, lower alkyl and substituted lower alkyl; R.sub.4 is L.sub.3-X-L.sub.4-G, wherein, L.sub.3, X and L.sub.4 taken together form a nitrogen containing heterocyclic ring; G is ##STR00058## wherein, R.sub.6, R.sub.7 and R.sub.8 are independently selected from among H, lower alkyl or substituted lower alkyl, lower heteroalkyl or substituted lower heteroalkyl, substituted or unsubstituted lower cycloalkyl, and substituted or unsubstituted lower heterocycloalkyl; or a pharmaceutically acceptable salt thereof.

2. The method of claim 1, wherein the B-cell proliferative disorder is a non-Hodgkin lymphoma selected from the group consisting of diffuse large B cell lymphoma, follicular lymphoma, mantle cell lymphoma and burkitt lymphoma.

3. The method of claim 1, wherein the B-cell proliferative disorder is Waldenstrom macroglobulinemia.

4. The method of claim 1, wherein the B-cell proliferative disorder is plasma cell myeloma.

5. The method of claim 1, wherein the irreversible covalent Btk inhibitor is administered orally.

6. The method of claim 1, wherein a covalent bond is formed between a portion of the acrylamide on the irreversible covalent Btk inhibitor and a portion of a cysteine residue on a Bruton's tyrosine kinase (Btk).

7. A method for treating a B-cell proliferative disorder comprising administering to a subject in need thereof an irreversible covalent Btk inhibitor, wherein the irreversible covalent Btk inhibitor comprises the structure ##STR00059##

8. The method of claim 7, wherein the B-cell proliferative disorder is a non-Hodgkin lymphoma selected from the group consisting of diffuse large B cell lymphoma, follicular lymphoma, mantle cell lymphoma and burkitt lymphoma.

9. The method of claim 7, wherein the B-cell proliferative disorder is Waldenstrom macroglobulinemia.

10. The method of claim 7, wherein the B-cell proliferative disorder is plasma cell myeloma.

11. The method of claim 7, wherein a covalent bond is formed between a portion of the irreversible covalent Btk inhibitor and a portion of a cysteine residue of a Bruton's tyrosine kinase (Btk).

12. The method of claim 1, wherein the cysteine residue is cysteine 481 of the Bruton's tyrosine kinase (Btk).

13. The method of claim 1, wherein the irreversible covalent Btk inhibitor has an 1050 of less than 1 .mu.M.

14. The method of claim 1, wherein the irreversible covalent Btk inhibitor has an 1050 of less than 0.2504.

15. The method of claim 1, wherein the irreversible covalent Btk inhibitor is administered orally.

16. The method of claim 1, wherein the subject is a human.

17. The method of claim 1, wherein the B-cell proliferative disorder is chronic lymphocytic leukemia.

18. The method of claim 7, wherein the B-cell proliferative disorder is chronic lymphocytic leukemia.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc